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ABSTRACT
Objective: Parkinson’s disease (PD) is the world’s second neurodegenerative disorder. Degeneration of dopaminergic neurons is the hallmark of the 
disease. Here is a novel approach to treat PD with a phenolic compound Sesamol (SA) and in combination with folic acid (FA).
Methods: The study was designed with five groups of animals and 6 rats in each group. The rats were infused with 6-hydroxydopamine (10 μg/2 μl 
in 0.1% ascorbic acid saline) once for the development of PD, Group 1 (control), Group 2 (lesion), Group 3 (lesion+SA), Group 4 (lesion+SA+FA), and 
Group 5 (lesion+L-dopa). The biochemical parameters such as glucose, triglycerides, protein, FA, thiobarbituric acid reactive substance (TBARS), and 
antioxidant profile in serum were estimated. The neurotransmitters level in striatum was estimated, and histopathology of striatum and midbrain 
tissues was carried out.
Results: The results showed that 6-hydroxydopamine induced lesion has a significant alteration in the level of glucose, triglycerides, protein and FA, 
whereas TBARS level was elevated and the activities of antioxidants and neurotransmitters level were reduced. This was significantly restored on SA 
and FA treatment. The lesion group shows an abnormal architecture of striatum and midbrain, whereas on SA and FA treatment there was minimal 
abnormality.
Conclusion: Thus, our study demonstrates that SA has a neuroprotective effect against 6-hydroxydopamine insult and showed a synergic effect when 
combined with FA.
Keywords: Parkinson’s disease, Sesamol, Folic acid, 6-hydroxydopamine, Neurotransmitter, Antioxidant.
INTRODUCTION
Neurodegenerative disorders are common among elderly people. 
Parkinson’s disease (PD) is the world’s second neurodegenerative 
disorder next to Alzheimer’s disease. The degeneration of 
dopaminergic neurons of substantia nigra pars compacta is the 
pathology of the disease. This kind of degeneration will reduce the level 
of neurotransmitter called dopamine (DA), which is involved in the 
locomotory event of the body. The DA depletion causes dysregulation in 
motor circuit of basal ganglia [1]. This leads to motor impairment such 
as bradykinesia, muscular rigidity, tremor, and postural instability. The 
degeneration of dopaminergic neurons may be due to oxidative stress, 
iron deposition, environmental toxins, mitochondrial dysfunction, and 
protein aggregation (Lewy body) [2]. The current medical strategy is 
just to alleviate the symptoms of the diseases. Although L-dopa was 
found to be the gold standard for the past 40 years, it causes side effects 
like sleep disturbance and emotional problems.
Oxidative stress is the basic precursor for almost all the deadly diseases 
and PD is also one among them [3]. Thus, it has been focused to find 
natural antioxidants such as curcumin, epigallocatechin-3-gallate, 
melatonin and so on to treat PD [4]. On this path, we have chosen the 
most powerful antioxidant sesamol (SA) present in sesame seeds. SA 
is a natural organic compound present in sesame oil extracted from 
Sesamum indicum that belongs to Pedaliaceae family. Numerous wild 
relative species are found in Africa and a smaller number in India. SA has 
various activities such as antioxidant, antifungal, neuroprotective [5], 
photoprotective [6], and hepatoprotective [7]. Along with SA, folic acid 
(FA) was combined, as FA involved in the synthesis of DA and it is to be 
noted that FA deficiency causes PD [8].
Therefore, this study was planned to evaluate the effect of SA in 
association with FA on 6-hydroxydopamine induced Parkinsonian 
animals in comparison with L-dopa. The general blood parameters 
such as glucose, triglycerides, protein, and FA were estimated. The 
activities of superoxide dismutase (SOD), catalase, glutathione 
peroxidase (GPx) and glutathione reductase (GRx), and the levels 
of glutathione (GSH), vitamin-C, vitamin-E and thiobarbituric acid 
reactive substance (TBARS) in serum of experimental animals were 
estimated. The levels of neurotransmitter such as DA, norepinephrine 
(NE), homovanillic acid (HVA), and 3,4-dihydroxy phenyl acetic acid 
(DOPAC) in striatum of animals were measured by flourimetric 
analysis. The tissue morphology of striatum and midbrain tissues was 
studied.
METHODS
Chemicals
6-hydroxydopamine, SA, L-dopa, apomorphine, FA, and ascorbic acid 
were purchased from Sigma-Aldrich. All the other chemicals used for 
the study were of analytical grade.
Experimental protocol
Male wistar rats of weight 200-250 g were purchased and maintained 
at 25±2°C in 12 hrs light/dark cycle with free access to food and 
water. The animal protocol was approved by the Institutional 
Animal Ethical Committee of Saveetha University (SU/BRULAC/
RD/004/2013). The rats were segregated into five groups, 6 rats in 
each group, Group 1 (control), Group 2 (lesion), Group 3 (lesion+SA), 
Group 4 (lesion+SA+FA), and Group 5 (lesion+L-dopa). The rats 
were anesthetized and infused with 6-hydroxydopamine at the 
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rate of 1 μl/minute, 2 μl of 6-hydroxydopamine (10 μg/2 μl in 0.1% 
ascorbic acid) was injected intrastriatal in right striatum once for the 
development of PD. The regions were located according to rat brain 
atlas (antero-posterior 0.5 mm, lateral 2.5 mm, dorso-ventral 4.5 mm 
relative to bregma, and ventral from dura). After 21 days, the disease 
development was confirmed by Apomorphine induced contralateral 
rotational test [9]. The animals were treated with SA (30 mg/kg body 
weight, intrapritonially), FA (5 mg/kg body weight, orally), and L-dopa 
(100 mg/kg, orally) for the next 24 days.
Sample collection
After the experimental period (45 days), animals were sacrificed by 
cervical dislocation. Anesthesia was not given as it alters the brain 
amines [10]. Blood was collected by cardiac puncher. The brains are 
removed immediately, the striatum and midbrain was dissected and 
processed for neurochemicals and histopathological study.
Biochemical parameters
Estimation of blood glucose
The blood glucose level was estimated by O-Toluidine method [11].
Estimation of protein
The protein was estimated by Lowry method [12].
Estimation of triglycerides
Triglycerides levels of experimental animals are estimated by the 
method of Rice [13].
Estimation of FA
FA in serum of experimental animals was estimated by the simple 
spectrophotometric method of Nagaraja et al. [14].
Estimation of antioxidant profile in serum of animals
Enzymatic antioxidants such as SOD [15], catalase [16], GPx [17] and 
GRx [18] and non-enzymatic antioxidant like GSH [19], vitamin-C [20] 
and vitamin-E [21]. Level of TBARS was also estimated as specified by 
Ohkawa et al. [22].
Estimation of neurotransmitter levels in striatum of animals
DA and NE estimation
The striatum was homogenized with acidified butanol and centrifuged 
at 800 g. Aliquots served as test samples. DA and NE were estimated by 
the method of Kari et al. [23]. The internal standard was prepared by 
known amount DA (1 µg) and NE (1 µg). The fluorescence of DA and NA 
was read at (385 and 485 nm) and (320 and 370 nm), respectively, with 
a slit wide of 10/10 nm.
HVA and DOPAC estimation
The homogenized striatal tissue sample was extracted with tris for HVA 
estimation and 1, 2-diaminoethen for DOPAC estimation according to 
method of Murphy et al. [24]. The fluorescence of HVA was measured 
at 315 and 430 nm and DOPAC was measured at 385 and 450 nm, with 
5 mm wide slit.
Histopathological study
The striatum and midbrain tissues were dissected from each group of 
animals. The tissues were fixed in 10% formalin and processed. The 
fixed tissues were embedded in paraffin wax and sectioned on the 
gelatine coated glass slide. The sections were stained with hematoxylin 
and eosin, then observed under light microscope. Brain tissue sections 
were examined for physiological changes and compared with the 
control group.
Statistical analysis
The results are expressed as mean±standard deviation one-way-
analysis of variance was applied to the data to derive the significance of 
the results. The p<0.001 was considered statistically significant.
RESULTS
Biochemical parameters
Estimation of glucose, triglycerides, and protein (Table 1) shows that 
there is a significant variation (p<0.001) between control animals 
(Group 1) and lesion animals (Group 2), and this was restored by 
SA and FA treatment. In comparison with lesion animals SA and FA 
treated animals showed a significant increase in the level of glucose, 
triglycerides, and protein than SA treated animals and L-dopa treated 
animals. The FA level shown in Table 1 indicates that there is a 
significant difference between control animals and lesion animals. The 
SA and FA treated animals show normal level of FA, which was highly 
significant p<0.001 when compared with lesion animals.
Enzymatic antioxidants activity in serum of experimental animals
Table 2 indicates the enzymatic antioxidants activities of SOD, catalase, 
GRx and GPx. There was a significant decrease in the activity of these 
enzymes in the lesion group animals when compared with control 
group animals. But on treatment with SA, FA and L-dopa the enzyme 
activity has increased. Among three treatment groups, the SA and FA 
treated animals shows significant (p<0.001) increase in the activity 
when compared with lesion animals.
Table 1: Biochemical parameters in serum of experimental animals
Parameters Group 1 (control) Group 2 (lesion) Group 3 (lesion+SA) Group 4 (lesion+SA+FA) Group 5 (lesion+L‑dopa)
Glucose (mg/dl) 111.89±6.19 96.54±5.09* 98.87±2.62NS 107.74±3.02# 96.34±1.07NS
Triglycerides (mg/dl) 74.46±1.17 62.55±1.59* 68.29±2.61# 71.09±1.54# 64.30±1.27NS
Protein (g/dl) 6.34±0.04 6.05±0.03* 6.24±0.03# 6.36±0.04# 6.23±0.07#
FA (ng/mL) 12.85±1.14 10.25±0.37* 11.19±0.43### 14.65±0.35# 10.85±0.57NS
The values were expressed as mean±SD. n=6, *p<0.001 comparison between Group 1 and 2. #p<0.001, ###p<0.05, NS: Non-significant comparison of Group 3, Group 4 
and Group 5 with Group 2. SA: Sesamol, FA: Folic acid, SD: Standard deviation
Table 2: Enzymatic antioxidants activity in serum of experimental animals
Enzymes Group 1  
(control)
Group 2  
(lesion)
Group 3  
(lesion+SA)
Group 4  
(lesion+SA+FA)
Group 5  
(lesion+L‑dopa)
SOD U/mg protein 5.41±0.15 3.14±0.32* 3.69±0.16# 4.75±0.26# 3.41±0.16##
Catalase (µmol H2O2 consumed/minute/mg protein) 31.96±1.24 21.37±0.59* 24.34±0.78## 30.29±4.67# 22.36±0.82NS
GPx (µmol NADPH oxidize/minute/mg protein) 3.65±0.10 1.97±0.23* 2.38±0.14# 3.20±0.17# 2.94±0.12#
GRx (µmol NADPH oxidize/minute/mg protein) 2.90±0.21 1.51±0.08* 1.81±0.10## 2.52±0.13# 2.10±0.11#
The values were expressed as mean±SD. n=6, *p<0.001 comparison between Group 1 and Group 2. #p<0.001, ##p<0.01, NS: Non-significant are comparison Group 3, 
Group 4 and Group 5 with Group 2. SA: Sesamol; FA: Folic acid, SD: Standard deviation, SOD: Superoxide dismutase, GPx: Glutathione peroxidiase, GRx: Glutathione 
reductase, NADPH: Nicotinamide adenine dinucleotide phosphate
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Non‑enzymatic antioxidants and TBARS level in serum of 
experimental animals
The levels of antioxidant such as GSH, vitamin-C, and vitamin-E of 
experimental animals were shown in Table 3. It was found that the 
antioxidant levels were significantly decreased in Lesion group animals 
when compared with control animals. This was restored by treatment. 
In comparison with Lesion group, Group 3, Group 4, and Group 5 
animals show a significant increase (p<0.001) in levels. Group 4 
animals show near normal level that is the SA and FA treated animals 
show a better effect than other groups. On the other hand, the level 
TBARS (Table 3) of Lesion group animals was significantly increased 
when compared with the control group. This was reduced significantly 
on SA and FA treatment.
Neurotransmitter levels in striatum of experimental animals
Fig. 1 shows the levels of DA, NE, DOPAC and HVA. It indicates the 
level of neurotransmitters in striatum of animals in Lesion group were 
significantly reduced (p<0.001) when compared with control group 
animals. On SA, FA, and L-dopa treatment the levels were increased. 
Among treatment groups, the SA and FA treated groups show increased 
levels of neurotransmitter which was highly significant (p<0.001) in 
comparison with lesion group.
Histopathological evidence of striatum and midbrain of 
experimental animals
Plate A1-A5 shows the histopathology of the striatum of experimental 
animals. The control animal (A1) shows the normal architecture of 
striatal tissue, whereas on 6-hydroxydopamine insult the changes 
such as cellular inflammation, vascular degeneration, and cytoplasmic 
vacuolation are visualized in lesion group animals (A2). There was 
an improvement on SA treated group (A3) and SA and FA treated 
group (A4), but there is no improvement in L-dopa treated group (A5). 
Among SA treated group and SA and FA treated group, the latter group 
shows better architecture of striatum similar to that of the control 
group.
Similarly, Plate B1-B5 showed the histology of midbrain of experimental 
animals. The control animals are with normal architecture, whereas 
the midbrain of lesion animals showed abnormalities like vascular 
degeneration and vaculation. These abnormalities are at minimal on 
SA treatment, and Group 4 showed less degeneration than Group 3. 
The L-dopa treated animals showed abnormality as in the case 
of lesion animals. The histopathological study evidenced that the 
degeneration of neuron in striatum and midbrain caused due to the 
6-hydroxydopamine insult was prevented by SA and FA administration. 
The degree of damage was higher in lesion group and L-dopa 
administrated group, this indicates that L-dopa does not prevent the 
degeneration of neurons whereas SA received animals showed a less 
degree of damage.
DISCUSSION
Our study demonstrates that the intrastriatal administration of 
6-hydroxydopamine reduces the striatal neurotransmitters level, 
antioxidant activity in serum and shows the abnormal architecture 
of striatal and Midbrain tissues. This kind of effect proves that the 
6-hydroxydopamine toxication is the ideal animal model for PD 
studies [25,26]. The levels of glucose, triglycerides, and protein 
were estimated, and we found significant alteration between the 
control, lesion and treated group. Previously, it was reported that 
immediately after L-dopa treatment the patients showed elevated 
level of hormones and plasma glucose and then it was reduced. 
At 1 year of chronic treatment of L-dopa, there was a decrease in 
glucose tolerance and associated with a delayed and exaggerated 
insulin response [27]. On the other hand, the SA and FA treatment 
have normalized these biological parameters indicating that they are 
safer to be consumed. Basically, phytochemicals are found to be safer 
than synthetically designed drugs. Many phytochemicals are used to 
treat chronic disease with no side effect [28-30]. This study suggests 
that SA is one among the safe phytochemicals that can be consumed. 
The study by Shooshtari et al. shows that the FA supplement has 
improved memory and motor activity of adult rats [31]. This supports 
our finding, as the SA and FA treated animals show normal level of FA 
in serum.
In our previous study, we have evaluated the behavioral activity of 
animals and antioxidant profile in the brain of experimental animals. 
We found that the animals induced with 6-hydroxydopamine showed 
abnormal behavioral activity and reduced antioxidant profile in the 
brain. On the other hand, there was an improvement in behavioral activity 
and antioxidant profile on SA and FA treatment [32]. Our study was in a 
harmony with other studies, such as quercetin showed neuroprotective 
effect against MPTP toxication in rats [33] and curcumin also showed 
neuroprotective effect against 6-hydroxydopamine toxicity [34]. As 
a well-known fact that the oxidative stress was found to be the main 
culprit for PD, it is important to evaluate the antioxidant profile of 
animals. In this study, the serum antioxidants were measured, and we 
found that the enzymatic antioxidant activities (SOD, catalase, GRx and 
GPx) and levels of GSH, vitamin-C and vitamin-E was reduced in the 
case of lesion group and it was restored by SA and FA treatment. On 
the other hand, the 6-hydroxydopamine induction increases the TBARS 
level in serum which in turn reduced on SA and FA treatment. The 
elevated level of TBARS indicates the occurrence of lipid peroxidation 
in the biological system. Lipid peroxidation is a complex reaction 
that involves the formation and propagation of lipid radical, uptake 
of oxygen, rearrangement in double bonds in unsaturated lipids and 
destruction in membrane lipids and producing a variety of breakdown 
products that includes alcohol, ketones, aldehyde and ether [35]. This 
lipid peroxidation chain reaction can be initiated by superoxide radical 
Table 3: Non‑enzymatic antioxidant activity in serum of experimental animals
Antioxidants Group 1 (control) Group 2 (lesion) Group 3 (lesion+SA) Group 4 (lesion+SA+FA) Group 5 (lesion+L‑dopa)
GSH (µg/mg protein) 4.80±0.31 2.49±0.41* 3.31±0.17# 4.67±0.12# 3.55±0.15#
Vitamin-C (mg/dl) 1.73±0.09 0.98±0.09* 1.25±0.08# 1.69±0.06# 1.46±0.04#
Vitamin-E (mg/dl) 1.84±0.08 1.02±0.07* 1.21±0.06# 1.66±0.08# 1.36±0.07#
The values were expressed as mean±SD, n=6.*p<0.001 comparison between Group 1 and Group 2. #p<0.001, NS: Non-significant are comparison Group 3, Group 4 and 
Group 5 with Group 2. SA: Sesamol, FA: Folic acid, GSH: Glutathione, SD: Standard deviation
Fig. 1: Neurotransmitter levels in stratum of experimental 
animals. The values were expressed as mean±standard deviation. 
n=6. *p<0.001 comparison between Groups 1 and 2. #p<0.001 
comparison of Group 3, Group 4, and Group 5 with Group 2. Group 1 
– Control, Group 2 – Lession, Group 3 – Sesamol treated, Group 4 – 
Sesamol and folic acid treated, and Group 5 – L‑dopa treated
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and nitric oxide [36]. The significant reduction in the TBARS level 
indicates the antioxidant scavenging activity of SA and FA.
The neurotransmitter levels in striatum of animals were depleted on 
6-hydroxydopamine toxication which was restored on SA, FA, and L-dopa 
treatment. The reduced level of DA and its metabolite is the hallmark of 
PD. The DA is responsible for movement and thus its reduction leads 
to motor impairment. The NE, DOPAC, and HVA are the derivatives of 
DA. Hence, the reduction in the DA level also influences the level of 
these derivatives. It was reported that on intrastriatal administration 
of 6-hydroxydopamine specifically the dopaminergic neurons are 
degenerated by increased oxidative stress and apoptosis [37,38]. The 
degeneration of dopaminergic neurons will lead to depletion in the level 
of DA as dopaminergic neurons are the major source of DA. Restoration 
of the levels of these neurotransmitters was achieved by two ways either 
DA replacement therapy such as L-dopa supplement or by prevention or 
protection of dopaminergic neurons from degeneration. The prior one 
may cause many side effects, so the prevention of degeneration must 
be a better one. From the present investigation, SA in association with 
FA may prevent the degeneration of dopaminergic neurons and it was 
evidenced by restoration of the level of neurotransmitters.
The histopathological evidence shows that morphological changes 
like cellular inflammation, vascular degeneration and cytoplasmic 
vacuolation induced by 6-hydroxydopamine was restored on SA and FA 
treatment. SA and FA have a protective effect on striatal neurons and 
show a clear texture of striatal tissue as similar to the control group. 
On the other hand, the L-dopa could only alleviate the symptoms and it 
does not prevent degeneration or protect the neurons.
SA is supposed to stop the further degeneration of neurons induced by 
6-hydroxydopamine and FA may act a supporting drug in preventing 
the degeneration from the day of administration. The neuronal number 
are found to be higher in the control group whereas the lesion animals 
showed only few neurons that are visible and this indicate that the 
neurons are degenerated due to 6-hydroxydopamine toxicity. A number 
of neurons are visualized more in SA and FA treated animals than lesion 
animals. This shows the neuroprotective effect of SA in association 
with FA. The present histopathological evidence was similar with 
other investigation which supports this study. The Lagenaria vulgaris 
showed neuroprotective effect against hypoxic neurotoxicity [39]. 
Similarly, valporic acid also showed a neuroprotective effect against 
6-hydroxydopamine toxicity [40].
Plate A1‑A5: Histopathology of striatal tissues (×100). A1: Group 1 (control) possess a normal architecture, A2: Group 2 (lesion) the 
abnormalities like cellular inflammation, vascular degeneration and cytoplasmic vaculation are visualized (indicated by arrow), 
A3: Group 3 (lesion+SA), A4: Group 4 (lesion+SA+FA) showed a minimal degeneration and cytoplasmic vaculation, A5: Gropu 5 (lesion+L‑
dopa) similar as in Group 2 animal. SA: Sesamol, FA: Folic acid
A1 A2 A3
A4 A5
Plate B1‑B5: Histopathology of mid‑brain tissues (×100). B1: Group 1 (control) possess a normal architecture, B2: Group 2 (lesion) 
the abnormalities like cellular inflammation, vascular degeneration and cytoplasmic vaculation are visualized (indicated by arrow), 
B3: Group 3 (lesion+SA), B4: Group 4 (lesion+SA+FA) showed a minimal degeneration and cytoplasmic vaculation, B5: Group 5 (lesion+L‑
dopa) similar as in Group 2 animal. SA: Sesamol, FA: Folic acid
B1 B2 B3
B4 B5
50
Asian J Pharm Clin Res, Vol 10, Issue 4, 2017, 46-50
 Shreen et al. 
CONCLUSION
The present investigation demonstrated that SA has nullified the 
toxicity of 6-hydroxydopamine. SA has reduced the oxidative stress, 
regularized antioxidant defense system, and increased the levels of 
neurotransmitters, prevented degeneration of dopaminergic neurons, 
which was evidenced by histopathological study of striatum and 
midbrain. In association with FA SA showed a better improvement. 
With these results, we emphasize that SA in association with FA shows 
better neuroprotective effect in treating Parkinsonian animals induced 
with 6-hydroxydopamine and it might serve as a novel therapeutic 
drug. Further investigations and clinical trials are required to justify 
the same.
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